RecallRadar

FDA Drug recall D-0745-2026

Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, D…

On 2026-08-12 the FDA classified a Class II recall of Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, D… by Zydus Pharmaceuticals Usa, citing CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0745-2026
ClassificationClass II
Statusongoing
Initiated2026-08-05
Published2026-08-12
Last updated2026-09-13 11:52 UTC
CompanyZydus Pharmaceuticals Usa
DistributionUS

Product

Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1159-3.

Reason

CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.

Identifiers

ndc70710-1159-3
ndc70710-1159-9
ndc70710-1159-1
ndc70710-1160-3
ndc70710-1160-9
ndc70710-1160-1
code_infoLot # E408618, Expiry: 11/30/2026, NDC #: 70710-1159-3

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0745-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.